The Combination Therapy of Fractional Laser and PRP Compared With Nanofat Grafting and PRP Synergy in Treating Striae Gravidarum.

Sponsor
First Affiliated Hospital of Jinan University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03328871
Collaborator
Science and Technology Program of Guangzhou (Other)
10
1
2
19
0.5

Study Details

Study Description

Brief Summary

Nowadays, multiple treatment modalities have been applied clinically to treat striae gravidarum, such as laser therapy, microdermabrasion, platelet-rich plasma injection(PRP), etc. To some extent, these treatments can improve striae gravidarum. In this clinical trial, the investigators are going to treat striae gravidarum by using two different kinds of combination therapies. One is fractional laser and PRP injection synergy, and the other one is treated by nanofat grafting with PRP injection.

Condition or Disease Intervention/Treatment Phase
  • Device: Fractional CO2 Laser
  • Procedure: Nanofat grafting
  • Procedure: Platelet-rich plasma (PRP) Injection
Phase 3

Detailed Description

The investigators will pick out two areas of most severe striae gravidarum on a participant's abdomen. One of the areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times. Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times. The participants were asked to come back 1、3、6、9 months after treatment for further follow-up.

Before and after the treatment, the striae gravidarum will be assessed subjectively by satisfaction assessment, dermatoscope and ultrasound, and objectively by immunohistochemical analysis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Combination Therapy of Fractional Laser and Platelet-Rich Plasma Injection Compared With Nanofat Grafting and Platelet-Rich Plasma Synergy in Treating Striae Gravidarum.
Actual Study Start Date :
Apr 1, 2017
Actual Primary Completion Date :
Dec 14, 2017
Anticipated Study Completion Date :
Nov 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Fractional CO2 Laser and PRP injection

One of the striae gravidarum areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times.

Device: Fractional CO2 Laser
Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.

Procedure: Platelet-rich plasma (PRP) Injection
PRP Injection will be applied once a month for 6 times.

Experimental: Nanofat grafting and PRP injection

Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times.

Procedure: Nanofat grafting
Nanofat grafting will be applied once every three months for 2 times.

Procedure: Platelet-rich plasma (PRP) Injection
PRP Injection will be applied once a month for 6 times.

Outcome Measures

Primary Outcome Measures

  1. Immunohistochemical analysis [Baseline and 15 months.]

    The tissue extracted will be taken for immunohistochemical analysis to observe the change of epidermal and dermal thickness, and the distribution and amount of elastic fiber and collagen fiber,etc.

Secondary Outcome Measures

  1. Dermatoscope [Baseline and at 3,6,9,12,15 months after the treatments.]

    The striae gravidarum will be assessed by dermatoscope to observe the pigmentation condition of striae after the application of laser or nanofat grafting with PRP injection.

  2. Ultrasound [Baseline and at 3,6,9,12,15 months after the treatments.]

    The striae gravidarum will be assessed by ultrasound in order to observe the change of dermal thickness of striae after the application of laser or nanofat grafting with PRP injection.

Other Outcome Measures

  1. Satisfaction assessments [After every sessions of treatments, and at 6,9,12,15 months.]

    The participants, investigators and physicians will fill in a satisfaction assessment about any complication during the treatments.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 35 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • The striae gravidarum was appeared within 3 years

  • Age ≤ 35 years old

  • Not in lactation

  • Not pregnancy within one year

Exclusion Criteria:
  • Skin allergy

  • Skin inflammation or wound

  • Platelet dysfunction syndrome

  • Take anticoagulant drugs

  • Acute or chronic infection

  • Chronic liver disease

  • Photodermatosis

  • Active vitiligo, psoriasis, systemic lupus erythematosus

  • Other clinical trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 First Affiliated Hospital of Jinan University Guangzhou Guangdong China 500011

Sponsors and Collaborators

  • First Affiliated Hospital of Jinan University
  • Science and Technology Program of Guangzhou

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Li-Ling Xiao, Associate Chief of Department of Plastic Surgery,The First Affiliated Hospital of Jinan University, Guangzhou, First Affiliated Hospital of Jinan University
ClinicalTrials.gov Identifier:
NCT03328871
Other Study ID Numbers:
  • LXiao FirstJinanU
First Posted:
Nov 1, 2017
Last Update Posted:
May 25, 2018
Last Verified:
May 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Li-Ling Xiao, Associate Chief of Department of Plastic Surgery,The First Affiliated Hospital of Jinan University, Guangzhou, First Affiliated Hospital of Jinan University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 25, 2018